PanFeng Feng

6PUBLICATIONS

4CO-AUTHORS

Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsClinical pharmacology and therapeuticsGene expression (incl. microarray and other genome-wide approaches)

Get your video featured.

Publish with JoVE

Get your video featured.

Publish with JoVE

Publications (6)

Sort by Publication Date:

|May 14, 2026

Economic evaluation of finotonlimab plus bevacizumab as first-line therapy for advanced hepatocellular carcinoma.

|Apr 16, 2026

Cycloastragenol Inhibits Colorectal Cancer Cell Metastasis via Epithelial-Mesenchymal Transition and the PI3K Signalling Pathway.

|Dec 22, 2025

Socazolimab combined with carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer: A cost-effectiveness analysis in China.

Lian Tang, Yong Chen, Shaoqing Zhan

|Dec 17, 2024

Xuebijing and somatostatin against acute pancreatitis: A systematic review and network pharmacology.

Ji-Ping Cao, Xiang-Hua Piao, Long-Xun Zhu

|Sep 27, 2024

RETRACTED: Arctigenin inhibits the progression of colorectal cancer through epithelial-mesenchymal transition via PI3K/Akt/mTOR signaling pathway.

Xiang-Fan Chen, Pei-Gen Liu, Nan Sheng

|Dec 15, 2022

Evaluation of Tag Single-Nucleotide Polymorphisms for Identifying HLA-B27 Status in a Chinese Han Population.

Nan Sheng, Wenwen Wang, Bo Zhang

Pageof 1

Frequent Collaborators

Nan Sheng

Wenwen Wang

Yingying Gao

Xiaoxiang Chen

Frequent Collaborators

Nan Sheng

Wenwen Wang

Yingying Gao

Xiaoxiang Chen